Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 16, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions. The following transaction prices are noted:
- Ordinary Shares: GBP 14.41 per share
- Ordinary Share ADRs: $57.68 per ADR
Material Changes
The filing details an increase in notional interests in Ordinary Shares and ADRs for various executives following the notional re-investment of the dividend paid to shareholders on July 12, 2007. No comparative financial data or material changes to the company's financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors
- This filing is a regulatory notification of insider share plan activity, not a financial results report.
- Transactions occurred on July 16, 2007, involving the re-investment of dividends paid on July 12, 2007.
- Specific share increases were recorded for executives including Dr. JP Garnier, Mr. A P Witty, and Mr. D M Stout, among others.
- Actual financial performance metrics for the period are not included in this text.